For ELISA: Use at a dilution of 1:100 - 1:500. For IHC-P and IHC-Fr: Use at an assay dependent dilution. For WB: Use at a dilution of 1:100 - 1:500. Use under non reducing conditions. Detects a band of approximately 62 kDa (predicted molecular weight: 52.7 kDa). Optimal dilutions/concentrations should be determined by the researcher.
Colo 320HSR cell lysates
This antibody may also be used to detect the commonly used c-myc 'tag'.
PBS, pH 7.4 with 0.01% sodium azide as preservative
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1.0 mg/ml (Please refer to the vial label for the specific concentration.)
Synthetic peptide: AEEQKLISEEDLL corresponding to the C-terminal amino acid 408-420 of human c-myc.
Protein G affinity purified
From hybridoma culture supernatant
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Myc Proto-Oncogene, Bhlh Transcription Factor,Mrtl,Mycc,Bhlhe39,C-Myc,Myc
The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin-dependent kinase, ERK2 and C-Jun N-terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown that c-Myc is essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells, and which brought extensive attention in the development of new therapeutic approach for cancer treatment.